CLL12: Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression

Sponsor

German CLL Study Group (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT02863718

Collaborator

Janssen-Cilag Ltd. (Industry)

515

Enrollment

Location

Arms

102.1

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a prospective, multicenter, randomized, placebo-controlled, double-blind phase III study that compares the efficacy and safety of oral ibrutinib in previously untreated Binet stage A CLL patients without treatment indication according to iwCLL guidelines but risk of early disease progression.

For event-free survival (EFS), an improvement from 24 months for untreated intermediate or (very) high risk CLL to 48 months for subjects treated with ibrutinib is considered clinically relevant. Ibrutinib / placebo is administered continuously orally until symptomatic disease progression, unacceptable toxicity, or voluntary treatment withdrawal, whichever occurs first.

Condition or Disease	Intervention/Treatment	Phase
Chronic Lymphocytic Leukemia	Drug: Ibrutinib Drug: Placebo	Phase 3

Detailed Description

The primary objective of the study is to demonstrate superiority of ibrutinib over placebo in prolonging EFS for subjects with treatment-naïve CLL stage A and intermediate or (very) high risk of disease progression. All subjects with intermediate, (very) high risk randomized to the experimental treatment arm will be treated up to active progressive disease with treatment indication according to iwCLL-Guidelines with the objective to demonstrate prolongation of EFS for the ibrutinib arm. EFS is defined as the time between randomization until active progressive disease with treatment indication according to the iwCLL-Guidelines with subsequent treatment for CLL or death.

The secondary objectives are:

To evaluate the prolongation of overall survival of ibrutinib versus placebo
To evaluate the safety of ibrutinib versus placebo

Study Design

Study Type:

Interventional

Actual Enrollment :

515 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia Patients With Risk of Early Disease Progression

Actual Study Start Date :

Apr 30, 2014

Actual Primary Completion Date :

Mar 7, 2019

Anticipated Study Completion Date :

Nov 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
No Intervention: Watch & wait Watch & wait
Placebo Comparator: Placebo 420 mg/d Placebo 420mg/d	Drug: Placebo Placebo 420mg daily
Active Comparator: Ibrutinib 420mg/d Ibrutinib 420mg/d	Drug: Ibrutinib Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily Other Names: Imbruvica

Arm

Intervention/Treatment

No Intervention: Watch & wait

Watch & wait

Placebo Comparator: Placebo 420 mg/d

Placebo 420mg/d

Drug: Placebo

Placebo 420mg daily

Active Comparator: Ibrutinib 420mg/d

Ibrutinib 420mg/d

Drug: Ibrutinib

Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily

Other Names:

Imbruvica

Outcome Measures

Primary Outcome Measures

Event-free survival (EFS) [randomization until progression, initiation of subsequent treatment for CLL or death by any cause, whichever occurs first, assessed for at at least 60 months]
EFS is defined as the time between the date of completed registration and time point of symptomatic disease progression with treatment indication, initiation of subsequent treatment for CLL or death by any cause, whichever occurs first. These will be counted as event for EFS.

Secondary Outcome Measures

Treatment-free survival [time of randomization until the date of initiation of subsequent treatment for CLL or death by any cause assessed for at at least 60 months]
The primary efficacy parameter is event-free survival (EFS) defined as the time of randomization until symptomatic disease progression with treatment indication, initiation of subsequent treatment for CLL or death by any cause, whichever occurs first
Progression-free survival (PFS) [the time of randomization until symptomatic disease progression (as defined by the updated iwCLL-guidelines) or death by any cause, whichever occurs first, assessed for at at least 60 months]
PFS is defined by the time of randomization until symptomatic disease progression (as defined by the updated iwCLL-guidelines) or death by any cause, whichever occurs first. These will be counted as event for PFS. Patients for whom no documented event for PFS is available at the time of analysis will be censored at the time point of last follow-up information they were assessed to be event-free.
Response rates (Overall response rate (ORR); Complete Remission (CR); Partial Remission (PR) [Overall response rate (ORR) achieved during treatment or within 6 months of end of treatment, complete response (CR) and partial response (PR) rates will be evaluated for at least 60 months or Progression whichever occurs first]
ORR, CR- and PR- rates are defined by the proportion of patients having achieved a response (CR/CRi and nPR/PR), CR/CRi and nPR/PR as best response respectively based on the respective population.
rate of Treatment-related adverse events [randomization until 28 days after the last dose of study drug]
Overall survival (OS) [date of randomization to the date of death for at least 60 months]
Respectively, for watch & wait- patients (study arm I) the date of completed registration will be used. Additionally, OS will also be calculated for the time period between first diagnosis of CLL and death due to any cause. Subjects who have not yet died at the time of analysis will be censored at the time of last follow-up information they were assessed to be alive. The exact cause of death will be recorded, with additional differentiation between CLL-related, treatment-related and other causes. Furthermore overall survival will be analyzed using a multivariate Cox regression model adjusted for risk category, study arm, and baseline prognostic factors

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Previously untreated CLL
Stage Binet A without need for treatment
Age ≥ 18 years
Life expectancy ≥ 6 months
ECOG 0 - 2
Signed written informed consent
Patient in the experimental arm is willing to use a highly effective contraceptive method
Male subjects in the experimental treatment arm (placebo / ibrutinib) must:
Agree to not donate semen during study drug therapy and for a period after end of study drug therapy.
For males these restrictions apply for 3 months after the last dose of study medication.
Agree not to share study medication with another person.
Be counseled about pregnancy precautions and risks of fetal exposure.
Willingness to inform the general practitioner

Exclusion Criteria:

Any prior CLL specific therapy
Prior treatment with Ibrutinib or BTK inhibitors
Chronic use of steroids in excess of prednisone 20mg/day or its equivalent
Active infections requiring systemic antibiotics
An life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion could compromise the subject's safety, interfere with the absorption or metabolism of Ibrutinib capsules, or put the study outcomes at undue risk
Pregnant or lactating females
Central nervous system (CNS) involvement as documented by spinal fluid cytology or imaging. Subjects who have signs or symptoms suggestive of leukemic meningitis or a history of leukemic meningitis must have a lumbar puncture procedure performed within two weeks prior to randomization
Known second malignancy that limits survival to less than two years
Known Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV) and/or active Hepatitis C Virus (HCV) infection.
Any of the following laboratory abnormalities:

Serum aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT)

2.5 x upper limit of normal (ULN)

Serum total bilirubin > 1.5 ULN (with the exception of Gilbert's Syndrome)
Creatinine clearance < 30ml/min

Requires anticoagulant with warfarin or phenoprocoumon
Requires anticoagulant with oral direct Xa Inhibitors (rivaroxaban, apixaban, edoxaban)
History of stroke or intracranial hemorrhage within 6 months prior to randomization
Requires treatment with strong CYP3A4/5 Inhibitors
Participation in any clinical study for CLL or having taken any investigational therapy which would interfere with the study drug for a disease other than CLL within 28 days prior to initiating treatment.
Prisoners or subjects who are institutionalized by regulatory or court order or persons who are in dependence to the sponsor or an investigator
Patients with uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia
For males these restrictions apply for 3 months after the last dose of study medication.
Agree not to share study medication with another person.
Be counseled about pregnancy precautions and risks of fetal exposure.
Willingness to inform the general practitioner
Requires anticoagulant with warfarin or phenoprocoumon
Requires anticoagulant with oral direct Xa inhibitors (rivaroxaban, apixaban, edoxaban)